Candin Safety & Efficacy Study for the Treatment of Warts

Status Completed

Clinical Trial Summary

The primary objective of this study is to determine the safety of Candin® (Candida albicans Skin Test Antigen) at a 0.3 ml dose level at up to 6 monthly injections for treating common warts (Verruca vulgaris).

Clinical Trial Description

The primary objective of this study is to determine the safety of Candin® (Candida albicans Skin Test Antigen) at either 0.3 mL dose levels at up to 6 monthly injections (a maximal, cumulative dose of 1.9 mL, including the delayed-type hypersensitivity (DTH) test) for treating common warts (Verruca vulgaris). A secondary objective is to understand the relative effectiveness of the 0.3 dose level for treating common warts, both those that were injected and those that were not injected as well as other types of warts that were not injected to allow a determination of appropriate dose levels to use in a future dose-ranging efficacy trial. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01757392
Study type	Interventional
Source	Nielsen BioSciences, Inc.
Contact
Status	Completed
Phase	Phase 2
Start date	September 2012
Completion date	December 2014

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05329961` - Immunogenicity of the 9vHPV Vaccination 2-dose Regimen Among Children 4 to 8 Years Old, An Exploratory Immunogenicity Study	Early Phase 1
Completed	`NCT05862844` - Promise Women Project	N/A
Active, not recruiting	`NCT04199078` - Clinical Trial to Explore Papilocare Gel Efficacy to Repair of the Cervico-vaginal Mucosa With HPV High Risk Lesions.	N/A
Recruiting	`NCT05566106` - Anal Follow-up of Patients With a Gynecological History of High-grade Lesion and More Induced HPV
Not yet recruiting	`NCT06229353` - Developing and Evaluating a Novel Approach to Improve HPV Vaccination Coverage Among High-risk, Under-immunized Adults Via the Emergency Department
Not yet recruiting	`NCT06436274` - Efficacy of Human Papillomavirus (HPV) Vaccination to Prevent Infection Among Women Living With HIV.	Phase 4
Active, not recruiting	`NCT04716127` - A Proximity-incentive Strategy for Cervical Cancer Screening	N/A
Recruiting	`NCT05210348` - Clinical Evaluation of Detection of High Risk HPV in Urine
Recruiting	`NCT05835947` - Anal Cancer Risk In Women
Not yet recruiting	`NCT03947775` - HPV-SAVE_Merck_Sub-Study for Preventing Recurrence of HSIL	Phase 2
Terminated	`NCT03404310` - Zinc Sulfate for Human Papillomavirus (HPV)	N/A
Recruiting	`NCT03302858` - A Safety and Efficacy Trial of Circumferential Anal Canal Radiofrequency Ablation for High-Grade Anal Intraepithelial Neoplasia Using the BARRX™ Anorectal Wand	Phase 2
Completed	`NCT03082950` - HPV Infections, Cancer of the Vulva and Therapeutical Success
Active, not recruiting	`NCT04950101` - Prevalence of Anal High-risk Human Papilloma Virus Infection and Abnormal Anal Cytology in Men Who Have Sex With Men Using Pre Exposure Prophylaxis	N/A
Recruiting	`NCT05146895` - A Cohort Study of Hyperthermia and Imiquimod for the Treatment of Flat Warts	N/A
Completed	`NCT04002154` - Clinical Trial to Explore the Papilocare Gel Efficacy to Repair the Cervico-vaginal Mucosa With Lesions Caused by HPV	N/A
Recruiting	`NCT04232917` - Study of 2LPAPI® on the Clearance of Genital HR-HPV Infections.	Phase 4
Active, not recruiting	`NCT03729518` - TORS De-Intensification Protocol Version 2.0: Dose and Volume Reduction in the Neck	N/A
Recruiting	`NCT05640700` - Vaginal Microbiome and HPV Pre-malignant and Cervical Dysplasia
Recruiting	`NCT05362669` - SMS Messaging for Invitation in the Cervical Cancer Screening Programme	N/A